Data / Form D filings / Blaze Bioscience, Inc.
Blaze Bioscience, Inc.: Form D filings
Blaze Bioscience, Inc., a biotechnology company in Seattle, WA, filed 15 Form D notices with the SEC between 2011 and 2024. The latest, on October 21, 2024, reports $8.1 million sold of a $20 million offering to 2 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 530 FAIRVIEW AVENUE N., SUITE 1400, Seattle, WA, 98109
- Phone
- (206) 535-8144
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1532854
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Oct 21, 2024 | New notice | $20,000,000 | $8,060,000 | $11,940,000 | 2 | Feb 15, 2024 | sec.gov |
| Oct 21, 2024 | New notice | $25,000,000 | $25,000,000 | 3 | Oct 6, 2022 | sec.gov | |
| Oct 21, 2024 | New notice | $15,000,000 | $15,000,000 | 6 | Oct 7, 2021 | sec.gov | |
| Oct 21, 2024 | New notice | $10,000,000 | $10,000,000 | 1 | Oct 30, 2020 | sec.gov | |
| Apr 8, 2020 | Amendment | $25,237,759 | $20,230,000 | $5,007,759 | 38 | Feb 1, 2019 | sec.gov |
| Feb 14, 2019 | New notice | $20,237,759 | $5,000,000 | $15,237,759 | 1 | Feb 1, 2019 | sec.gov |
| May 15, 2018 | New notice | $5,000,000 | $3,000,000 | $2,000,000 | 1 | May 10, 2018 | sec.gov |
| Oct 10, 2017 | New notice | $18,105,620 | $16,108,197 | $1,997,423 | 32 | Oct 3, 2017 | sec.gov |
| Jun 22, 2017 | New notice | $5,000,000 | $554,000 | $4,446,000 | 5 | Jun 8, 2017 | sec.gov |
| Jan 12, 2016 | New notice | $4,990,000 | $991,000 | $3,999,000 | 8 | Dec 31, 2015 | sec.gov |
| Jun 25, 2015 | Amendment | $15,000,000 | $9,711,998 | $5,288,002 | 27 | Jun 14, 2013 | sec.gov |
| Jun 26, 2014 | Amendment | $15,000,000 | $9,626,598 | $5,373,402 | 23 | Jun 14, 2013 | sec.gov |
| Jun 27, 2013 | New notice | $15,000,000 | $8,080,400 | $6,919,600 | 5 | Jun 14, 2013 | sec.gov |
| Jun 19, 2012 | New notice | $10,721,462 | $6,378,179 | $4,343,283 | 19 | Jun 6, 2012 | sec.gov |
| Oct 17, 2011 | New notice | $1,500,000 | $725,000 | $775,000 | 6 | Oct 3, 2011 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Heather L. Franklin | Director | |
| Steven R. Daly | Executive Officer, Director | |
| Lawrence Patrick Hughes | Director | |
| James C. Towne | Executive Officer, Director | |
| Ludmila R. Lobanova | Executive Officer | |
| Jan K. Ohrstrom | Director |
Other biotechnology companies in Washington that filed recently
- Key Proteo, Inc. $2.3 million · Oct 23, 2026
- Inmedix, Inc. $4 million · Oct 22, 2026
- Q-Immune, Inc. $25,000 · Sep 28, 2026
- Hexamer Therapeutics, Inc $500,000 · Sep 15, 2026
- MalarVx, Inc. $125,000 · Aug 25, 2026
- Strella Biotechnology, Inc. $1.8 million · Aug 14, 2026
Every Form D from the week of Oct 21, 2024 · All recent filings in Washington · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Blaze Bioscience, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.